Introduction
Patients with advanced HIV disease commonly take a large number of medications that are active against HIV, that treat or prevent opportunistic infections and that prevent the symptoms of HIV itself or those produced by the other medications. Many of these medications have overlapping toxicities, and share the same methods of elimination from the body, leading to varied drug interactions.
This article seeks to highlight those drugs that are used in HIV infected patients which are most commonly associated with drug interactions, the reasons for these interactions and to help physicians and pharmacists make decisions about which of the interactions are clinically significant. By examining available data on the toxicity, formulation and pharmacokinetics of these different medications charts and explanatory notes have been compiled.
Pharmacodynamic Interactions (tables [1] [2] [3] [4] Additive toxicity One or a number of the main side effects of the two drugs overlap and can lead to increased toxicity. The classification of this toxicity is denoted by a letter:
M-Myelotoxicity P-Pancreatitis N-Peripheral neuropathy K-Nephrotoxicity L-Hepatotoxicity The clinical significance of this interaction is as below. Increased Serum Levels This is usually due to inhibition of metabolism by the liver or excretion via the kidneys, and can lead to increased toxicity. The drug that has been affected is indicated by the direction of the arrow (table  1) . The clinical significance of this interaction is described below.
Decreased Serum Levels This is often caused by an increase in metabolism by the liver as a result of the use of drugs which induce liver enzymes such as rifampicin, or by a decrease in the absorption of the drug from the gastrointestinal tract such as the bioavailability of ketoconazole is reduced by the administration of drugs which increase gastric pH. The clinical significance of this interaction is as below. K. The renal excretion of zidovudine, didanosine, zalcitabine and stavudine may be inhibited by drugs that cause renal toxicity such as aminoglycosides, IV amphotericin, foscarnet, cidofovir and IV pentamidine. Dosage reductions are recommended by the manufacturers for zidovudine, didanosine, and stavudine in patients with renal impairment. The dose of zalcitabine should also be reduced but neither the degree of reduction nor information about when this reduction should take place is available.
Didanosine is unstable at the pH found in the stomach. Therefore it is supplied as a chewable/dispersible tablet with dihydroxyaluminium sodium carbonate, magnesium hydroxide and sodium citrate as buffer to increase the pH of the stomach and thus its bioavailability. The presence of the buffer may interfere with absorption of a number of drugs by two different mechanisms. By increasing the pH it may reduce the solubility and thus absorption of acid soluble drugs eg dapsone, ketoconazole, itraconazole, pyrimethamine, trimethoprim and rifampicin.'9 Alternatively, the aluminium and magnesium ions contained in the chewable/dispersible tablet formulation may bind (chelate) the drug molecules eg ciprofloxacin, and tetracyclines (not in the table) thus preventing their absorption.2 To reduce the effect of didanosine on the absorption of other drugs they should be administered at least 2 hours apart.
Pharmacodynamic interactions
The most frequent adverse effects after chronic use of zidovudine are related to bone marrow toxicity and result in anaemia and neutropenia. Those of didanosine and zalcitabine are peripheral neuropathy and pancreatitis. Zalcitabine has also been reported to cause thrombocytopenia in approximately 4% of patients. The major dose limiting toxicities of stavudine are peripheral neuropathy and increased hepatic transaminases.4 The combined use of ganciclovir and zidovudine has been reported to be poorly tolerated in patients with HIV and serious cytomegalovirus (CMV) disease. In one study 82% of patients on this combination developed severe to life threatening haematological complications.20 Zidovudine should be stopped whilst patients are receiving high dose intravenous ganciclovir. It may be reintroduced (generally at a lower dose) when the dose of ganciclovir is reduced, or the patient is transferred to the oral formulation.
The combination of foscarnet with zidovudine is haematologically better tolerated than that of ganciclovir and zidovudine. However, one small study has reported increased transfusion.requirements in patients receiving both zidovudine and foscarnet. This occurred mainly during the treatment period.2' Care should be taken with other drugs reported to cause haematological toxicity (see table 1, opposite page).
Drugs that cause peripheral neuropathy should be used with caution in combination with didanosine, zalcitabine, or stavudine and drugs that cause pancreatitis in combination with didanosine and zalcitabine. If this is not possible in an acute clinical situation, then the antiretroviral medication should be stopped whilst treatment is taking place and restarted after a one-to-two week wash out period. and fatigue on initiation of zidovudine. These symptoms resolved when the aciclovir was stopped. 23 In practice zidovudine and aciclovir are frequently used together without this problem being encountered.
Zidovudine and pyrimethamine and pyrimethaminelsulphadiazine Zidovudine has been found to antagonise the toxoplasmocidal effect of a low concentration of pyrimethamine in vitro, and in vitro synergism between pyrimethamine and sulphadiazine against Toxoplasma gondii is reversed by zidovudine. Zidovudine also antagonises the therapeutic effect of pyrimethamine in mice acutely infected with Tgondii. The clinical significance of this finding is unclear. 24 Zidovudine and stavudine In cell cultures zidovudine inhibits the phosphorylation of stavudine, while stavudine has no effect on the phosphorylation of zidovudine. This finding may potentially influence the decision to use stavudine and zidovudine as combination therapy for HIV infection. 25 Zidovudineldidanosine and ganciclovir In vitro work has suggested that ganciclovir antagonises the anti-HIV effect of zidovudine/didanosine.26
Didanosine and drugs with a low bioavailability such as atovaquone and oral ganciclovir The buffer in didanosine may induce diarrhoea in some patients. In patients taking drugs with a low bioavailability this may reduce absorption and make the medication ineffective.27
Antifungal medication: amphotericin, ketoconazole, itraconazole, fluconazole and flucytosine (Table 2 see opposite  page) Antifungal medications are widely used in the treatment of the HIV positive patient. Severity of infection ranges from superficial oral candida to cryptococcal meningitis and pulmonary aspergillosis. The sensitivity of the organism, site of infection, drug toxicity and interactions will often dictate the choice of therapy to be used. Amphotericin, although extremely nephrotoxic is the treatment of choice in severe infections.
Pharmacokinetic interactions
Ketoconazole, and itraconazole share many of the same interactions. They require an acid environment for optimal absorption, are extensively metabolised in the liver and excreted almost exclusively in the faeces and the urine. In contrast the absorption of fluconazole is unaffected by gastric pH and it is minimally metabolised, with 80% being excreted unchanged in the urine. Fluconazole is the only azole for which dose reduction is necessary in renal impairment and care needs to be taken with nephrotoxic drugs.
All three azoles inhibit the cytochrome P450 liver metabolising isoenzyme CYP3A4 leading to increased serum levels of many drugs (see Phenytoin toxicity has been observed when fluconazole was added to patients' treatment regimens. 33 The metabolism of ketoconazole, itraconazole, and fluconazole is accelerated by drugs which induce liver enzymes such as rifampicin, rifabutin, phenytoin etc. Almost negligible serum levels of itraconazole have been reported in a patient taking concurrent rifampicin and itraconazole,3435 and poor treatment outcomes and clinical relapse have been reported in patients taking fluconazole and rifampicin.3637 Carbamazepine and phenobarbitone have also been shown to induce itraconazole metabolism. 38 Isoniazid decreases plasma levels of ketoconazole and so may possibly have the same effect on itraconazole levels. 39 The absorption of ketoconazole and itraconazole is reduced as the pH of the stomach increases. In a study comparing the absorption of ketoconazole and fluconazole in patients receiving intravenous cimetidine, in order to titrate their stomach acid to pH 6.0 and above, there was a dramatic effect on the disposition of ketoconazole. Reductions of 90% in AUC and maximum concentrations were seen. 40 The disposition of fluconazole was unaffected. To increase the solubility and thus absorption of ketoconazole and itraconazole patients are advised to take them with an acidic carbonated beverage eg lemon and lime carbonated drinks, carbonated water or cola.4' Any drug which increases gastric pH including didanosine, should be taken at least two hours after ketoconazole or itraconazole, and where possible they should be taken with or after food (except for itraconazole liquid which contains a buffer and is better absorbed in a fasted state).
Flucytosine is excreted mostly unchanged in the urine. It is extremely myelotoxic and toxicity is related to serum levels. Serum levels must be monitored closely especially when it is being used in combination with a nephrotoxic agent eg amphotericin.
Pharmacodynamic interactions
The main toxicities of amphotericin are fever and chills on administration, abnormal renal function, hypokalaemia and hypomagnesaemia. Acute liver failure, normochromic normocytic anaemia, thrombocytopenia, leucopenia and other haematological abnormalities have also been reported. The use of amphotericin with other nephrotoxic drugs should be avoided wherever possible or if this is not possible it should be used with extreme caution (see table  2 ). Acute, rapidly progressive, renal failure has been documented with the simultaneous use of IV amphotericin and IV pentamidine. 42 The main toxicities of the azoles are rash and elevations of liver function tests. Unless abnormal liver function tests are present the use of azoles with other potentially hepatotoxic drugs is not precluded. There is a possible interaction between alcohol and ketoconazole (see under miscellaneous).
As flucytosine is extremely myelotoxic, its use with other myelotoxic drugs should be avoided. If (see table 3 ), the effect of rifampicin being greater than that of rifabutin. The effects of enzyme induction may be seen within a few days, but maximal induction takes more than a week to occur.
The effect of rifampicin on the metabolism of azoles (see above), corticosteroids, clarithromycin, dapsone, methadone, the oral contraceptive, phenytoin and warfarin (not in table) are clinically very important. For example; it is recommended that the dose of corticosteroids be doubled in some instances. 46 It is reported that prophylaxis of Pneumocystis carinii pneumonia with dapsone failed because of the interaction with rifampicin47 and serum levels of phenytoin, and the clinical effectiveness of warfarin and the oral contraceptive are reduced.4849 Rifampicin increases the rate of metabolism of many opiates including methadone and withdrawal symptoms may be induced. 50 In one prospective study, rifampicin, and to a lesser extent rifabutin, were shown to significantly reduce the mean serum levels of clarithromycin.51 This has raised doubts as to the effectiveness of this combination for the treatment of MAI and further studies are required. Clarithromycin in turn has been shown to inhibit the metabolism of rifabutin leading to an increased incidence of uveitis and neutropenia. Fluconazole and potentially the other azoles have also been shown to increase plasma levels of rifabutin. [52] [53] [54] [55] [56] [57] Clarithromycin and azithromycin are both macrolide antibiotics. Clarithromycin is extensively hepatically metabolised to its active metabolite 14-hydroxy clarithromycin. The half life of clarithromycin and its metabolite are increased in the presence of renal impairment, leading to the recommendation that the dose is reduced in this situation. The proportion of absorbed azithromycin that undergoes hepatic biotransformation is unknown. Several metabolites have been identified but these are not thought to possess significant antimicrobial activity. The primary route of azithromycin elimination may be via the bile and faeces, although transintestinal elimination has also been proposed as a primary route of elimination. Less than 6% of a dose of azithromycin is recovered in the urine within one week of administration. 58 The mechanism of the inhibition of hepatic cytochrome P450 enzymes by macrolide antibiotics has been well documented. 59 Clarithromycin shares many of the interactions of erythromycin. It appears to inhibit the metabolism of carbamazepine leading to increased serum concentrations,60 it inhibits the metabolism of the non-sedating antihistamines and cisapride increasing the risk of cardiac arrhymias.6' The potential for other interactions seen with erythromycin needs to be borne in mind eg increased levels of digoxin and theophylline, and enhanced clinical effects of corticosteroids warfarin62 and vinblastine.63
In contrast to clarithromycin, azithromycin has been shown to be relatively free of drug interactions. It does not exhibit the interaction with the non-sedating antihistamines and cisapride.61 However, the possibilities of interactions should be considered as an increase in neutropenia comparable to that which occurs with clarithromycin was reported when azithromycin was used in conjunction with rifabutin.Y Pharmacodynamic interactions With all these drugs most frequently encountered side effects involve the gastrointestinal tract, for example nausea and vomiting.
Rifampicin and rifabutin will stain body secretions red/orange colour, rifabutin will also stain the skin. Both have the potential to increase liver enzymes, and to cause neutropenia. High serum concentrations of rifabutin increase the incidence of uveitis and are also associated with a syndrome of arthralgia/ arthritis.52 57 4 ).
Aciclovir is well tolerated. At high intravenous doses aciclovir has been reported to crystalise in the kidneys. Therefore care should be taken with the use of other potentially nephrotoxic drugs and the dose of aciclovir should be reduced if nephrotoxicity occurs.
The dose limiting toxicities of ganciclovir are neutropenia and thrombocytopenia. Care should be taken in using ganciclovir with other myelotoxic drugs as an increased incidence of myelotoxicity has been reported with the concurrent use of zidovudine and ganciclovir (see above).
Foscarnet and cidofovir are both nephrotoxic. As with amphotericin (see above) concurrent use of other nephrotoxic drugs should be avoided where possible. Foscarnet and corticosteroids Amphotericin and foscamet cause potassium depletion, therefore from the interaction between amphotericin and corticosteroids it follows that corticosteroids may increase the potassium depletion seen with foscamet.
Part 2 In the second part of this article the newer anti retrovirals will be considered: indinavir, saquinavir, ritonavir and lamivudine (3TC).
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